SCHEMBL13802438

SCHEMBL13802438

O=C(O)Cc1c(-c2ccccc2)n(C(=O)c2ccc(OC(F)(F)F)cc2)c2ccccc12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 5/20 0.69
PTGS2 P35354 3/20 0.52
PTGS1 P23219 2/20 0.52
AGTR1 P30556 1/20 0.48
AKR1C3 P42330 6/20 0.47
AKR1C2 P52895 6/20 0.47
LMNA P02545 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2D6 P10635 2/20 0.47
CYP2C9 P11712 2/20 0.47
HIF1A Q16665 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
TSHR P16473 1/20 0.47
NFKB1 P19838 1/20 0.47
PTGIR P43119 1/20 0.44
ESR1 P03372 1/20 0.43
ESR2 Q92731 1/20 0.43
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
PTGES O14684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4205369 0.87 ABCB1 (0.69) ABCB1PTGS2PTGS1AKR1C3AKR1C2
SCHEMBL13802431 0.75 PTGS2 (0.58) ABCB1PTGS2PTGS1AKR1C3AKR1C2
SCHEMBL13802432 0.75 PTGS2 (0.59) ABCB1PTGS2PTGS1AKR1C3AKR1C2
SCHEMBL13802419 0.74 AKR1C3 (0.58) ABCB1PTGS1AKR1C3AKR1C2KDM4E
SCHEMBL13802393 0.74 AKR1C3 (0.71) ABCB1PTGS2PTGS1AKR1C3AKR1C2
SCHEMBL13802395 0.74 AKR1C3 (0.68) ABCB1PTGS2PTGS1AKR1C3AKR1C2
SCHEMBL23602950 0.74 PTGS2 (0.74) ABCB1PTGS2PTGS1AKR1C3AKR1C2
SCHEMBL13802380 0.74 AKR1C3 (0.78) ABCB1PTGS2PTGS1AKR1C3AKR1C2
SCHEMBL5554099 0.73 AKR1C3 (0.83) ABCB1PTGS2PTGS1AKR1C3AKR1C2
SCHEMBL3005490 0.73 PTGS1 (0.71) ABCB1PTGS2PTGS1AKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090155903-A1 PHARMACEUTICAL COMPOSITION AND METHOD MYRIAD GENETICS, INCORPORATED (US) 2009-06-18 US disclosed
US-20090155903-A1 PHARMACEUTICAL COMPOSITION AND METHOD MYRIAD GENETICS, INCORPORATED (US) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090155903-A1 PHARMACEUTICAL COMPOSITION AND METHOD APP, PSEN2, PSEN1 ABCB1 139/4885PTGS2 2066/4885PTGS1 2198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.